Guggenheim upgrades Editas Medicine stock to Buy

Published on 10/07/2026 at 01:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose to USD 11.89 million from USD 3.58 million in Q2 2026. For Editas Medicine stock, cash reached USD 211.6 million on June 30, 2026.

EDIT, US28106W1036, Illustration mit AI erstellt.

On September 23, 2026, Guggenheim upgraded Editas Medicine stock from Neutral to Buy and set a USD 5.00 price target, according to PriceTargets.com. The call places the clinical-stage gene-editing company between a USD 2.73 Nasdaq last quote on October 6, 2026 and a target that is 83.15 percent above that primary-exchange price.

Second-quarter revenue expands

Editas reported collaboration and other research and development revenue of USD 11.89 million for the three months ended June 30, 2026, compared with USD 3.58 million in the same period of 2025, according to GlobeNewswire. That USD 8.31 million increase came from deferred revenue recognized after rights under the Bristol Myers collaboration expired.

The same second-quarter report showed a net loss of USD 18.23 million, or USD 0.15 per diluted share, versus a USD 53.24 million loss, or USD 0.63 per share, a year earlier. Research and development spending increased to USD 20.18 million from USD 16.18 million, keeping the expense base tied to preclinical work on EDIT-401.

Cash funds EDIT-401 development

Cash and cash equivalents stood at USD 211.6 million on June 30, 2026, compared with USD 146.6 million on December 31, 2025, and the company said the balance should fund operations and capital needs into the second half of 2028, according to GlobeNewswire. The financial runway matters because EDIT-401 is moving from preclinical development toward a planned Phase 1/2 study for heterozygous familial hypercholesterolemia.

Editas said it expected to submit a Clinical Trial Notification in Australia in August 2026 and planned a data update in the first quarter of 2027. The company also appointed Dan Ory, M.D., as chief medical officer effective September 8, 2026, according to Editas Medicine.

Nasdaq range keeps risk visible

Finance data showed a Nasdaq market capitalization of USD 419.0 million on October 6, 2026, with a 52-week range of USD 1.66 to USD 4.54. The primary-exchange quote was last at USD 2.73 on October 6, 2026 at 4:00 p.m. ET, down 2.15 percent from USD 2.79, a separate market reference from the euro quotation used for German investors.

Euro prior close sets the reference

The last Lang & Schwarz prior close was EUR 2.43 on October 5, 2026. The company is still valued primarily on clinical execution, cash duration and the conversion of EDIT-401 preclinical evidence into human data rather than on recurring product revenue.

The further course of trading is shown by the continuously updated real-time quote of Editas Medicine stock.